Search clinical trials for: mRNA-1273.529 vaccine

Total 10179 results

ModernaTX, Inc.

Completed

A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

SARS-CoV-2

United Kingdom
ModernaTX, Inc.

Completed

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

SARS-CoV-2

United States
National Institute of Allergy and Infectious Diseases...

Completed

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

COVID-19

United States
Chulalongkorn University
BioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaborators

Recruiting

Safety and Immunogenicity of ChulaCov19 BNA159 mRNA Vaccine

Safety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditions

Thailand
Sheba Medical Center
ModernaTX, Inc.

Completed

Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults (SH-MO-214)

COVID-19 | SARS CoV 2 Infection | COVID-19 Pandemic | Immunogenicity

Israel
Indonesia University
Dr Cipto Mangunkusumo General Hospital

Completed

The Differences of Oocyte Maturation, Granulosa Cell Apoptosis Index Between Electroacupuncture And Sham Groups IVF

in Vitro Fertilization | Acupuncture | Oocyte Maturation | BCL2 Gene mRNA Overexpression

Indonesia
Maria Joyera Rodríguez

Withdrawn

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination (VAX-TRES)

Covid19
ModernaTX, Inc.

Completed

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

SARS-CoV-2

United States
ModernaTX, Inc.

Active, not recruiting

A Study of Modified mRNA Vaccines in Healthy Adults

Cytomegalovirus | SARS-CoV-2 | Seasonal Influenza | Respiratory Syncytial Virus

United States
ModernaTX, Inc.

Completed

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Influenza | SARS-CoV-2 | RSV

United Kingdom, Australia, United States
University Medical Center Groningen

Active, not recruiting

Vaccination Against COVID-19 in Cancer (VOICE)

Cancer

Netherlands
Umeå University

Not yet recruiting

Risk of COVID-19 Infection After Vaccination

Covid19 | Vaccination; Infection
Shanghai Jiao Tong University School of Medicine

Recruiting

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Medullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine Carcinoma

China
Korea University Guro Hospital
Korea University Anam Hospital; Ajou University School of Medicine; Korean Center... and other collaborators

Recruiting

COVID-19 Vaccine Reactogenicity and Immunogenicity

COVID-19 | Vaccine Adverse Reaction | Vaccine Immune Response

Korea, Republic of
ModernaTX, Inc.

Completed

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

Influenza

United States
Judit Pich Martínez

Completed

A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy

HIV-infection

Spain
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus Infection

Australia, United States
ModernaTX, Inc.

Completed

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Influenza | SARS-CoV-2

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
Karolinska Institutet

Completed

Polymorphids an mRNA Expression in Obese Genes

Polymorphism | mRNA Expression

Sweden
National Institute of Allergy and Infectious Diseases...

Completed

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

Covid19 | SARS-CoV2 Infection

United States
ModernaTX, Inc.

Active, not recruiting

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults

Epstein-Barr Virus Infection

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults

Influenza

United States
Quratis Inc.

Active, not recruiting

Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

COVID-19 | SARS-CoV-2

Korea, Republic of
Tan Tock Seng Hospital
KK Women's and Children's Hospital; Duke-NUS Graduate Medical School; A*Star

Recruiting

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PRIBIVAC)

COVID-19

Singapore
CureVac

Active, not recruiting

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Glioblastoma

Belgium, Germany, Netherlands
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Active, not recruiting

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

HIV Infections

United States
ModernaTX, Inc.

Completed

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

Seasonal Influenza

United States
GlaxoSmithKline

Recruiting

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Influenza, Human

United States
CHANGHEE LEE
Purdue University; LG Electronics Inc.

Completed

Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study (miRNA_Chip)

BCL2 Gene mRNA Overexpression

Korea, Republic of
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority

Completed

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

SARS-CoV-2

United States
ModernaTX, Inc.

Active, not recruiting

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

Smallpox | Mpox

United Kingdom
ModernaTX, Inc.

Completed

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Cytomegalovirus Infection

United States
ModernaTX, Inc.

Recruiting

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

SARS-CoV-2

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
ModernaTX, Inc.

Completed

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

COVID-19 | COVID-19 Immunisation

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1283.222 Injection Compared With mRNA-1273.222 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

COVID-19

United States, United Kingdom, Canada
ModernaTX, Inc.

Completed

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

SARS-CoV-2

United States, Canada
ModernaTX, Inc.

Completed

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

SARS-CoV-2

United States
Erasmus Medical Center
University Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaborators

Active, not recruiting

SWITCH ON: Analysing the Immunogenicity of Additional Booster Vaccinations in HCW (SWITCHON)

Covid-19 Vaccination

Netherlands
ModernaTX, Inc.

Completed

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older

Seasonal Influenza

Spain, United States, Denmark, Poland, United Kingdom, Germany, Canada, Taiwan, Bulgaria, Netherlands, Estonia
ModernaTX, Inc.

Recruiting

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Respiratory Syncytial Virus | Human Metapneumovirus

United Kingdom, Spain, United States, Australia, Canada, Poland, South Africa, Panama
National Cancer Institute (NCI)
Boston University; Duke University; University of Southern California; University... and other collaborators

Completed

Study of Lung Health Among Workers Exposed to Diesel Exhaust

Inflammation Biomarkers | mRNA Expression | nitroPAH Adducts

China
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (RSVictory)

Respiratory Syncytial Virus

United States
ModernaTX, Inc.
Biomedical Advanced Research and Development Authority

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)

SARS-CoV-2

United States, Dominican Republic
GlaxoSmithKline

Recruiting

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Influenza, Human

United States
GlaxoSmithKline

Active, not recruiting

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

COVID-19

United States
Jinling Hospital, China
Jiangsu Synthgene Biotechnology Co.Ltd.

Recruiting

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
ModernaTX, Inc.

Active, not recruiting

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303)

Seasonal Influenza

United States
Assistance Publique - Hôpitaux de Paris
COVIREIVAC

Active, not recruiting

Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine (ARNCOMBI)

Adult Who Received a First Dose of an mRNA Vaccine (Pfizer-BioNTech or Moderna) and Need to Receive a Second Dose

France
ModernaTX, Inc.

Active, not recruiting

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Norovirus Acute Gastroenteritis

United States

3

Subscribe